INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
25/07/2026
Voltar para busca
Dado oficial do USPTO
ALTAVOL
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
43
Atualização mais recente
25/07/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 10
Data de depósito
15/01/2024
Data de registro
29/07/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
29/07/2025
Última transação
25/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
03
Localização do titular
CH
Examinador
DUBIN, DAVID I
Unidade examinadora
L70
Localização atual
Historical data usage
Titulares e representantes
Titulares
Novartis AG
Representantes
Maury M. Tepper, III Tepper & Eyster, PLLC
Classificação técnica
Classes Nice
Classe 5Classe 10
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Anti-infectives; Anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; pharmaceutical preparations for the treatment of dermatological diseases; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune systemthe metabolic systemthe endocrine systemthe musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in the treatment of hematology diseases; pharmaceutical preparations for use in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in the treatment of ophthalmology diseases; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
Classe 10
Medical apparatus and instruments for diagnosing and treating cardiovascular diseases; Medical apparatus and instruments for diagnosing and treating dermatological diseases; medical apparatus and instruments for diagnosing and treating respiratory diseases and disorders; medical apparatus and instruments for diagnosing and treating central nervous system diseases; medical apparatus and instruments for the diagnosis and treatment of gastro-intestinal diseases; medical apparatus and instruments for the diagnosispreventiontreatment of diseases and disorders of the autoimmune systemthe metabolic systemthe endocrine systemthe musculo-skeletal system and the genitourinary system; medical apparatus and instruments for the diagnosispreventiontreatment of hematology diseases and disorders; medical apparatus and instruments for use in tissue and organ transplantation surgery; medical apparatus and instruments for the diagnosispreventiontreatment of eye diseases and eye conditions; medical apparatus and instruments for the diagnosispreventiontreatment of heart rhythm disorders; medical apparatus and instruments for the diagnosispreventiontreatment of immune system diseases and disorders; medical apparatus and instruments for the diagnosispreventiontreatment of kidney diseases; medical apparatus and instruments for the diagnosispreventiontreatment of diabetes; medical apparatus and instruments for the diagnosispreventiontreatment of hypertension; medical apparatus and instruments for the diagnosispreventiontreatment of skin disorders; medical apparatus and instruments for the diagnosispreventiontreatment of urinary diseases and disorders; medical apparatus and instruments for the diagnosispreventiontreatment of ophthalmological diseases and disorders; medical apparatus and instruments for the diagnosispreventiontreatment of cancer and tumors; medical apparatus and instruments for the diagnosispreventiontreatment of allergies; medical apparatus and instruments for the diagnosispreventiontreatment of bone diseases; medical apparatus and instruments for the diagnosispreventiontreatment of respiratory diseases and asthma; radiological apparatus for medical purposes and instruments being radiological apparatus for medical purposes; genetic testing apparatus for medical purposes and instruments being genetic testing apparatus for medical purposes; electromagnetic drug delivery apparatus for medical use and instruments being electromagnetic drug delivery apparatus for medical use; medical apparatus and instruments for diagnostic radiopharmaceutical use; medical apparatus and instruments for facilitating the inhalation of pharmaceutical preparations; apparatus and instruments being medical diagnostic apparatus for testing DNA and RNA samples for medical use; medical apparatusinfusion and injection devices for administering drugs; medical apparatus and instruments being medical apparatus for introducing pharmaceutical preparations into the human body
Publicações
Histórico de despachos e eventos da marca no USPTO.
43 publicações encontradas
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
10/07/2026
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/03/2026
FICS
FINAL DISPOSITION NOTICE SENT TO IB
19/02/2026
FIMP
FINAL DISPOSITION PROCESSED
19/02/2026
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
19/02/2026
NURC
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
02/12/2025
A7OK
AMENDMENT UNDER SECTION 7 - PROCESSED
10/11/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
03/11/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
29/10/2025
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
24/10/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
08/10/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
08/10/2025
ES7R
TEAS SECTION 7 REQUEST RECEIVED
20/08/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
29/07/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
29/07/2025
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
09/07/2025
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
13/06/2025
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
15/05/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
29/04/2025
PUBO
PUBLISHED FOR OPPOSITION
29/04/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
23/04/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/04/2025
LOPR
LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN
31/03/2025
LOPT
LETTER OF PROTEST EVIDENCE FORWARDED
31/03/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/02/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/02/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/02/2025
RFNT
REFUSAL PROCESSED BY IB
17/01/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/01/2025
RFRR
REFUSAL PROCESSED BY MPU
02/01/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
17/12/2024
CNRT
NON-FINAL ACTION WRITTEN
16/12/2024
DOCK
ASSIGNED TO EXAMINER
09/08/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
29/05/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
29/05/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
29/05/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
29/05/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
29/05/2024
MAFR
APPLICATION FILING RECEIPT MAILED
21/05/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
21/05/2024
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
15/05/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/05/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ALTAVOL ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.